8:00 am Registration & Networking Coffee

8:50 am Chair’s Opening Remarks

• Divya Mathur Associate Research Fellow, Pfizer

Assessing Current Limitations of Cell Engagers including Strategies to Mitigate Toxicities to Ensure Patient Safety

9:00 am XTENylated Protease Activated T Cell Engagers: XPATS – A Novel Format to Mitigate the On-target, Off-tumor Problem

• Volker Schellenberger President & CTO , Amunix

9:30 am T Cell Engaging Antibody Circuits (TEAC): Focusing Immune Activation to the Cancer Cell Surface to Widen the Therapeutic Index

• Patricia Giblin VP of Biology, Revitope

10:00 am TriTACs Are T Cell Engaging Drugs for Treatment of Solid Tumors

• Rick Austin Senior Director of Biology Research, Harpoon

10:30 am Speed Networking & Morning Refreshments

11:30 am Sponsored talk by MaxCyte: Details to be confirmed

12:00 pm Panel Discussion: Exploiting the High Protease Concentration in the Tumor Microenvironment to Reduce Toxicity

• Holger Wesche CSO, Harpoon Therapeutics Inc.
• Volker Schellenberger President & CTO , Amunix
• Chad May Senior Vice President - Research & Development, Maverick Therapeutics

12:45 pm Networking Lunch

Improving the Therapeutic Window of Cell Engagers: Addressing Half-Life and Cytokine Release Syndrome

2:00 pm Discovering and Designing the Next Generation of T cell Engagers

• Omid Vafa CBO, TeneoBio

2:30 pm Optimizing Therapeutic Index and Other Properties with Potency Reduction and Bivalent Target Engagement

• John Desjarlais CSO, Xencor

3:00 pm CB307: A Novel T cell Enhancing Humabody Bispecific

• James Legg SVP of Research, Crescendo Biologics

3:30 pm Afternoon Refreshments & Networking

Review of Current Clinical Data

4:00 pm Translating Preclinical BiTE® Data to the Clinic

• Julie Bailis Principal Scientist, Amgen

4:30 pm Flotetuzumab: An Experimental CD123 x CD3 Bispecific DART Molecule for the Treatment of AML

• Jan Davidson Director of Clinical Development & Research , Macrogenics

5:00 pm AMV564 Relieves Immune Suppression Through Selective Targeting of CD33

• Victoria Smith CSO, Amphivena

5:30 pm Chair’s Closing Remarks & End of Day One